MKMichael R. Kolber

Michael R. Kolber

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael R. Kolber has a total of 109 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Interaction Between Chronotype and the Timing of Antihypertensive Medication on Cardiovascular Events and Death

    by Scott R. Garrison, Jeffrey A. Bakal, Michael R. Kolber, Christina S. Korownyk, Lee A. Green, Jessica E. M. Kirkwood, Finlay A. McAlister, Raj S. Padwal, Richard Lewanczuk, Michael D. Hill, et al.


  • Open Access

    Lignes directrices simplifiées de PEER sur les lipides : actualisation 2023

    by Michael R. Kolber, Scott Klarenbach, Michel Cauchon, Mike Cotterill, Loren Regier, Raelene D. Marceau, Norah Duggan, Rebecca Whitley, Alex S. Halme, Tanis Poshtar, et al.

    Objectif Actualiser le guide de pratique clinique de 2015 et présenter une approche simplifiée de la prise en charge des lipides dans la prévention des maladies cardiovasculaires (MCV) en première ligne. Méthodes Conformément aux recommandations de l’Institute of Medicine dans Clinical Practice Guidelines We Can Trust, un panel pancanadien d’experts multidisciplinaires en lignes directrices a été formé. Ce panel était représentatif des cliniciens en soins primaires, libre de tout conflit d’intérêts avec l’industrie, et il tenait compte des points de vue des patients. Une équipe distincte, responsable des données probantes scientifiques, a passé en revue l’information sur les statines, l’ézétimibe, les inhibiteurs de la proprotéine convertase subtilisine-kexine de type 9, les fibrates, les chélateurs des acides biliaires, la niacine et les suppléments d’omega-3 (acide docosahexaénoïque avec acide eicosapentaénoïque [EPA] ou ester éthylique de l’EPA seul [icosapent]), ainsi que sur la réponse à 11 questions supplémentaires. Le panel des lignes directrices a finalisé les recommandations en utilisant la méthodologie GRADE (Grading of Recommendations Assessment, Development and Evaluation). Recommandations Toutes les recommandations sont présentées de manière à être centrées sur le patient et conçues en ayant à l’esprit les besoins des médecins de famille et des autres cliniciens des soins primaires. De nombreuses recommandations sont semblables à celles publiées en 2015. Les statines demeurent le traitement de première intention pour la prévention tant primaire que secondaire des MCV, et le régime méditerranéen et l’activité physique sont recommandés pour réduire le risque cardiovasculaire (en prévention primaire et secondaire). Le panel des lignes directrices a recommandé de ne pas utiliser le dosage des lipoprotéines a, des apolipoprotéines B ou le score calcique coronarien (SCC) dans l’évaluation du risque cardiovasculaire, et de ne pas cibler de seuils précis de taux lipidiques. L’équipe a aussi passé en revue de nouvelles données concernant les acides gras omega-3 (y compris l’ester éthylique d’EAP [icosapent]) et les inhibiteurs de la proprotéine convertase subtilisine-kexine de type 9, et a précisé les moments où il convient de procéder à une prise de décision partagée avec les patients sur les interventions pour diminuer le risque cardiovasculaire. Conclusion Ces lignes directrices actualisées et fondées sur des données probantes présentent une approche simplifiée de la prise en charge des lipides pour la prévention et le traitement des MCV. Ce guide de pratique clinique a été conçu par et pour des professionnels de la santé en soins primaires et leurs patients.


  • Open Access

    PEER simplified lipid guideline 2023 update

    by Michael R. Kolber, Scott Klarenbach, Michel Cauchon, Mike Cotterill, Loren Regier, Raelene D. Marceau, Norah Duggan, Rebecca Whitley, Alex S. Halme, Tanis Poshtar, et al.

    Objective To update the 2015 clinical practice guideline and provide a simplified approach to lipid management in the prevention of cardiovascular disease (CVD) for primary care. Methods Following the Institute of Medicine’s Clinical Practice Guidelines We Can Trust, a multidisciplinary, pan-Canadian guideline panel was formed. This panel was represented by primary care providers, free from conflicts of interest with industry, and included the patient perspective. A separate scientific evidence team performed evidence reviews on statins, ezetimibe, proprotein convertase subtilisin-kexin type 9 inhibitors, fibrates, bile acid sequestrants, niacin, and omega-3 supplements (docosahexaenoic acid with eicosapentaenoic acid [EPA] or EPA ethyl ester alone [icosapent]), as well as on 11 supplemental questions. Recommendations were finalized by the guideline panel through use of the Grading of Recommendations Assessment, Development and Evaluation methodology. Recommendations All recommendations are presented in a patient-centred manner designed with the needs of family physicians and other primary care providers in mind. Many recommendations are similar to those published in 2015. Statins remain first-line therapy for both primary and secondary CVD prevention, and the Mediterranean diet and physical activity are recommended to reduce cardiovascular risk (primary and secondary prevention). The guideline panel recommended against using lipoprotein a, apolipoprotein B, or coronary artery calcium levels when assessing cardiovascular risk, and recommended against targeting specific lipid levels. The team also reviewed new evidence pertaining to omega-3 fatty acids (including EPA ethyl ester [icosapent]) and proprotein convertase subtilisin-kexin type 9 inhibitors, and outlined when to engage in informed shared decision making with patients on interventions to lower cardiovascular risk. Conclusion These updated evidence-based guidelines provide a simplified approach to lipid management for the prevention and management of CVD.. These guidelines were created by and for primary health care professionals and their patients.


  • Open Access

    Evaluation of the quality of colonoscopies performed by Alberta North Zone surgeons, family physicians and internists: a quality improvement initiative

    by Michael R. Kolber, Peter J. Miles, Marcus D. Shaw, Hilgard Goosen, Dereck C.M. Mok

    Background: In Canada, endoscopy is primarily performed by gastroenterologists and surgeons, and some studies report that colonoscopies performed by nongastroenterologists have more complications and higher rates of future colorectal cancer. Our objective was to determine whether rural-based nongastroenterologist endoscopists are achieving quality benchmarks in colonoscopy. Methods: This quality improvement initiative prospectively evaluated 6 key performance indicators (KPIs) (cecal intubations, polyp detection [males and females; for first-time colonoscopies on patients aged ≥ 50 yr], bowel preparations, patient comfort and withdrawal times) on consecutive colonoscopies performed by participating Alberta North Zone endoscopists. The study period was June 2018 to March 2020. Overall and individual endoscopist’s KPIs were compared with standard benchmarks. Additional performance indicators included mean number of polyps per colonoscopy and an exploration of study-defined sedation-related level of consciousness. Results: Data were collected on 6212 colonoscopies performed by 16 endoscopists (9 surgeons, 5 family physicians and 2 internists) in 6 hospitals. All 6 KPI benchmarks were achieved when results were pooled over all endoscopists in the study. Overall, cecal intubation occurred in 6006 of 6209 (96.7%, 95% confidence interval 94.5%–99.0%) cases. Polyp detection was 65.9% (592/898) and 49.8% (348/699) for male and female patients, respectively, aged 50 years or older. Variability in individual endoscopist results existed, especially for the mean number of polyps per 100 colonoscopies and sedation-related level of consciousness. Interpretation: Overall, Alberta North Zone endoscopists are performing high-quality colonoscopies, collectively achieving all 6 KPIs. To understand endoscopic performance and encourage individual and group reflection on endoscopic practices, Canadian endoscopists are encouraged to participate in similar colonoscopy quality initiative studies.


  • PEER systematic review of randomized controlled trials

    by Michael R. Kolber, Joey Ton, Betsy Thomas, Jessica Kirkwood, Samantha Moe, Nicolas Dugré, Karenn Chan, Adrienne J. Lindblad, James McCormack, Scott Garrison, et al.

    Objective To determine the proportion of chronic low back pain patients who achieve a clinically meaningful response from different pharmacologic and nonpharmacologic treatments. Data sources MEDLINE, EMBASE, Cochrane Library, and gray literature search. Study selection Published randomized controlled trials (RCTs) that reported a responder analysis of adults with chronic low back pain treated with any of the following 15 interventions: oral or topical nonsteroidal anti-inflammatory drugs (NSAIDs), exercise, acupuncture, spinal manipulation therapy, corticosteroid injections, acetaminophen, oral opioids, anticonvulsants, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors, cannabinoids, oral muscle relaxants, or topical rubefacients. Synthesis A total of 63 RCTs were included. There was moderate certainty that exercise (risk ratio [RR] of 1.71; 95% CI 1.37 to 2.15; number needed to treat [NNT] of 7), oral NSAIDs (RR = 1.44; 95% CI 1.17 to 1.78; NNT = 6), and SNRIs (duloxetine; RR = 1.25; 95% CI 1.13 to 1.38; NNT = 10) provide clinically meaningful benefits to patients with chronic low back pain. Exercise was the only intervention with sustained benefit (up to 48 weeks). There was low certainty that spinal manipulation therapy and topical rubefacients benefit patients. The benefit of acupuncture disappeared in higher-quality, longer (> 4 weeks) trials. Very low-quality evidence demonstrated that corticosteroid injections are ineffective. Patients treated with opioids had a greater likelihood of discontinuing treatment owing to an adverse event (number needed to harm of 5) than continuing treatment to derive any clinically meaningful benefit (NNT = 16), while those treated with SNRIs (duloxetine) had a similar likelihood of continuing treatment to attain benefit (NNT = 10) as those discontinuing the medication owing to an adverse event (number need to harm of 11). One trial each of anticonvulsants and topical NSAIDs found similar benefit to that of placebo. No RCTs of acetaminophen, cannabinoids, muscle relaxants, selective serotonin reuptake inhibitors, or tricyclic antidepressants met the inclusion criteria. Conclusion Exercise, oral NSAIDs, and SNRIs (duloxetine) provide a clinically meaningful reduction in pain, with exercise being the only intervention that demonstrated sustained benefit after the intervention ended. Future high-quality trials that report responder analyses are required to provide a better understanding of the benefits and harms of interventions for patients with chronic low back pain. Résumé Objectif Déterminer la proportion de patients souffrant de lombalgie chronique qui ressentent un soulagement cliniquement significatif grâce à différents traitements pharmacologiques et non pharmacologiques. Sources des données Recension dans MEDLINE, EMBASE, la bibliothèque Cochrane et la documentation parallèle. Sélection des études Les études randomisées contrôlées (ERC) publiées qui rapportaient une analyse des réponses d’adultes souffrant de lombalgie chronique, traités au moyen de l’une ou l’autre des 15 interventions suivantes : anti-inflammatoires non stéroïdiens (AINS) oraux ou topiques, exercice, acupuncture, thérapie par manipulation de la colonne, injections de corticostéroïdes, acétaminophène, opioïdes oraux, anticonvulsifs, antidépresseurs tricycliques, inhibiteurs de la recapture de la sérotonine-norépinéphrine (IRSN), inhibiteurs sélectifs de la recapture de la sérotonine, cannabinoïdes, relaxants musculaires oraux ou rubéfiants topiques. Synthèse La revue incluait 63 ERC. Selon des données modérément sûres, l’exercice (rapport de risques-avantages [RR] de 1,71; IC à 95 % de 1,37 à 2,15; nombre de sujets à traiter [NST] = 7), les AINS oraux (RR = 1,44; IC à 95 % de 1,17 à 1,78; NST = 6) et les IRSN (duloxétine; RR = 1,25; IC à 95 % de 1,13 à 1,38; NST = 10) procurent des bienfaits cliniquement significatifs aux patients souffrant de lombalgie chronique. L’exercice était la seule intervention dont les bienfaits étaient durables (jusqu’à 48 semaines). Les données étaient d’une faible certitude pour indiquer que la thérapie par manipulation de la colonne et les rubéfiants topiques étaient bénéfiques pour les patients. Les bienfaits de l’acupuncture disparaissaient dans les essais de qualité supérieure et de plus longue durée (≥ 4 semaines). Des données probantes de très faible qualité démontraient que les injections de corticostéroïdes étaient inefficaces. Il était plus probable que les patients traités avec des opioïdes cessent le traitement en raison d’un événement indésirable (nombre nécessaire pour nuire de 5) qu’ils le poursuivent pour obtenir un bienfait cliniquement significatif (NST = 16), tandis que chez les patients traités avec des IRSN (duloxétine), la probabilité était semblable, qu’ils poursuivent le traitement pour obtenir des bienfaits (NST = 10) ou qu’ils cessent le médicament en raison d’un événement indésirable (nombre nécessaire pour nuire de 11). Deux études, l’une sur les anticonvulsifs et l’autre sur les AINS, ont constaté des bienfaits semblables à ceux du placebo. Aucune ERC sur l’acétaminophène, les cannabinoïdes, les relaxants musculaires, les inhibiteurs sélectifs de la recapture de la sérotonine ou les antidépresseurs tricycliques n’a satisfaisait aux critères d’inclusion. Conclusion...


    • 1 December 2018
      • Vol. 64  (12) , E553-E560

    Alberta Family Physician Electronic End copy study Quality of 1769 colonoscopies performed by rural Canadian family physicians

    by Michael R. Kolber, Nicole Olivier, Oksana Babenko, Ryan Torrie, Lee Green

    Objective To determine whether rural FP colonoscopists in Alberta are achieving benchmarks in colonoscopy quality. Design Prospective, multicentre observational study. Setting Alberta. Participants Nine FP colonoscopists. Main outcome measures Proportion of successful cecal intubations; proportion of patients aged 50 and older with pathologically confirmed adenomas; mean number of adenomas per colonoscopy; and serious adverse events related to colonoscopy. Results In this 6-month study, 9 rural FPs in Alberta performed 1769 colonoscopies. Overall, all key colonoscopy quality benchmarks were met or exceeded. The proportion of successful cecal intubations was 97.9% (95% CI 97.2% to 98.6%). The proportion of male and female patients aged 50 and older whose first-time colonoscopy results revealed an adenoma was 67.4% (95% CI 62.4% to 72.7%) and 51.1% (95% CI 45.5% to 56.7%), respectively. There were 120 adenomas, 36 advanced adenomas, and 1 colon cancer case per 100 colonoscopies. There were 2 postpolypectomy bleeds and no other serious complications. Conclusion Alberta rural FP colonoscopists are meeting benchmarks in colonoscopy quality. Ongoing electronic collection of endoscopy quality markers should be encouraged. Supporting and training rural FPs who perform endoscopy might help alleviate current wait times and improve access for rural Canadian patients.


  • Skills, Practice Patterns, and Knowledge of Canadian Family Physician Endoscopists

    by Michael R. Kolber, Shelley Ross

    BACKGROUND AND OBJECTIVES: In Canada, few family physicians (FPs) perform endoscopy. Conflicting evidence exists on the quality of endoscopy performed by Canadian FPs, which may be explained by differing skillsets of these endoscopists. The objective of this study was to perform the first exploration of the practice, skills, and knowledge of Canadian FP endoscopists. METHODS: A cross-sectional survey, including direct knowledge test, was used. RESULTS: Twenty Canadian FP endoscopists completed the survey. Ninety-five percent practice outside urban centres, all perform gastroscopies, and 85% perform colonoscopies and polypectomies. These endoscopists are performing about 32 procedures per month. They are using split bowel preparations, performing rectal retroflexion, and tattooing advanced lesions, all characteristics of a quality endoscopist or program. Self-identified knowledge gaps identified included caring for patients with inflammatory bowel disease and staging rectal cancer. Direct testing found gaps in describing Barrett's esophagitis and managing anticoagulated patients who require endoscopy. CONCLUSIONS: Canadian FP endoscopists appear to be providing quality endoscopic exams and should be supported and encouraged to continue to provide care of rural Canadian patients with gastrointestinal concerns. Future training and continuing education events aimed at this group of endoscopists should target identified knowledge gaps.

    • 1 September 2016
      • Vol. 62  (9) , E547-E554

    Helicobacter pylori status among patients undergoing gastroscopy in rural northern Alberta

    by Isabelle N. Colmers-Gray, Ben Vandermeer, Robert I. Greidanus, Michael R. Kolber

    Objective To determine the Helicobacter pylori status of patients who underwent gastroscopy. Design Retrospective chart review. Setting Peace River Community Health Centre in rural northwestern Alberta. Participants Data were collected from patients who had a gastroscopy performed by either of 2 family physicians between January 1, 2011, and December 31, 2012. Main outcome measures The proportion of patients who had positive test results for H pylori overall and among first-time gastroscopy patients. For first-time gastroscopy patients, the associations between H pylori infection and patient age, sex, residence, and procedural indications and findings were explored. Results A total of 251 gastroscopies were conducted in 229 unique patients during the study period. Overall, 12.4% (95% CI 8.3% to 16.4%) of patients had positive results for H pylori and among the 159 first-time gastroscopy patients, 17.6% (95% CI 11.7% to 23.5%) had positive test results for H pylori. Helicobacter pylori status did not differ significantly by geography, sex, or age. The prevalence of H pylori was higher among patients with H pylori-related indications for gastroscopy (such as dyspepsia and upper gastrointestinal tract bleeding) than among patients with other indications; however, H pylori infection was not statistically significantly greater in patients diagnosed with peptic ulcer disease. Conclusion The prevalence of H pylori infection among patients undergoing gastroscopy in rural northern Alberta appears lower than other Canadian estimates. In regions with low H pylori rates, patients with dyspepsia might be better served by acid suppression and nonsteroidal anti-inflammatory drug cessation before investigating for H pylori infection. Population-based research is required to further describe regional differences in H pylori rates.